Previous close | 37.93 |
Open | 38.36 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 2900 |
Day's range | 38.22 - 39.71 |
52-week range | 24.10 - 42.37 |
Volume | 12,809,414 |
Avg. volume | 11,020,521 |
Market cap | 55.997B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 15.18 |
EPS (TTM) | N/A |
Earnings date | 27 Apr 2021 - 03 May 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 43.36 |
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of $1.07 billion, subject to closing adjustments. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. With 2021 net sales anticipated to be approximately $200 million, the Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures. Foundational to its urology portfolio is the proprietary MOSES™ technology, which has demonstrated differentiated clinical outcomes and efficiency in the management of patients with kidney stones.